<DOC>
	<DOCNO>NCT00002557</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness etoposide without doxorubicin methotrexate treat patient mycosis fungoides .</brief_summary>
	<brief_title>Combination Chemotherapy Patients With Advanced Recurrent Mycosis Fungoides</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response rate patient Stage III/IV recurrent mycosis fungoides Sezary syndrome treat oral etoposide , addition doxorubicin , methotrexate poor responder . II . Assess change hematologic immunologic status tumor patient . OUTLINE : Patients treat sequentially Regimens A , B , C depend response . The following acronym use : CF Leucovorin calcium , NSC-3590 DOX Doxorubicin , NSC-123127 MTX Methotrexate , NSC-740 VP-16 Etoposide , NSC-141540 Regimen A : Single-Agent Chemotherapy . VP-16 . Regimen B : 2-Drug Combination Chemotherapy . VP-16/DOX . Regimen C : 3-Drug Combination Chemotherapy . VP-16/DOX/MTX . PROJECTED ACCRUAL : Study duration least 3 year anticipate accrual 3 patients/year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Stage III/IV mycosis fungoides Sezary syndrome Stage I/II cutaneous Tcell lymphoma relapse follow interferon therapy also eligible PATIENT CHARACTERISTICS : Age : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Prior interferon alpha Stage I/II disease allow Chemotherapy : Prior isotretinoin Stage I/II disease allow Endocrine therapy : Prior topical steroid Stage I/II disease allow Radiotherapy : Prior ultraviolet therapy Stage I/II disease allow Prior xray therapy Stage I/II disease allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>